BSE
CIPLA

CIPLA LTD.

Drug Manufacturers-General
Healthcare

Prices are adjusted according to historical splits.

CIPLA LTD. Stock Price

Vitals

Today's Low:
₹1235.7
Today's High:
₹1259.85
Open Price:
₹1244.1
52W Low:
₹845.1433
52W High:
₹1277.55
Prev. Close:
₹1246.7
Volume:
24433

Company Statistics

Market Cap.:
₹1,003.18 billion
Book Value:
290.005
Revenue TTM:
₹235.11 billion
Operating Margin TTM:
18.6%
Gross Profit TTM:
₹145.01 billion
Profit Margin:
13.23%
Return on Assets TTM:
8.52%
Return on Equity TTM:
12.64%

Company Profile

CIPLA LTD. had its IPO on under the ticker symbol CIPLA.

The company operates in the Healthcare sector and Drug Manufacturers-General industry. CIPLA LTD. has a staff strength of 32,323 employees.

Stock update

Shares of CIPLA LTD. opened at ₹1244.1 at the start of the last trading session i.e. 2023-09-13.

The stocks traded within a range of ₹1235.7 - ₹1259.85, and closed at ₹1239.25.

This is a -0.6% slip from the previous day's closing price.

A total volume of 24,433 shares were traded at the close of the day’s session.

In the last one week, shares of CIPLA LTD. have increased by +0.03%.

CIPLA LTD.'s Key Ratios

CIPLA LTD. has a market cap of ₹1,003.18 billion, indicating a price to book ratio of 4.0842 and a price to sales ratio of 4.1117.

In the last 12-months CIPLA LTD.’s revenue was ₹235.11 billion with a gross profit of ₹145.01 billion and an EBITDA of ₹52.93 billion. The EBITDA ratio measures CIPLA LTD.'s overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, CIPLA LTD.’s operating margin was 18.6% while its return on assets stood at 8.52% with a return of equity of 12.64%.

In Q2, CIPLA LTD.’s quarterly earnings growth was a positive 45.1% while revenue growth was a positive 17.9%.

CIPLA LTD.’s PE and PEG Ratio

Forward PE
21.5054
Trailing PE
35.7112
PEG

Its diluted EPS in the last 12-months stands at ₹34.8 per share while it has a forward price to earnings multiple of 21.5054 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into CIPLA LTD.’s profitability.

CIPLA LTD. stock is trading at a EV to sales ratio of 3.9049 and a EV to EBITDA ratio of 18.1228. Its price to sales ratio in the trailing 12-months stood at 4.1117.

CIPLA LTD. stock pays annual dividends of ₹0 per share, indicating a yield of 0.68% and a payout ratio of 20.84%.

Balance sheet and cash flow metrics

Total Assets
₹294.63 billion
Total Liabilities
₹51.10 billion
Operating Cash Flow
₹0
Capital Expenditure
₹0
Dividend Payout Ratio
20.84%

CIPLA LTD. ended 2024 with ₹294.63 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹294.63 billion while shareholder equity stood at ₹234.08 billion.

CIPLA LTD. ended 2024 with ₹0 in deferred long-term liabilities, ₹51.10 billion in other current liabilities, 1614300000.00 in common stock, ₹232.46 billion in retained earnings and ₹29.84 billion in goodwill. Its cash balance stood at ₹6.28 billion and cash and short-term investments were ₹67.35 billion. The company’s total short-term debt was ₹0 while long-term debt stood at ₹0.00.

CIPLA LTD.’s total current assets stands at ₹172.75 billion while long-term investments were ₹0 and short-term investments were ₹51.70 billion. Its net receivables were ₹40.57 billion compared to accounts payable of ₹24.57 billion and inventory worth ₹51.56 billion.

In 2024, CIPLA LTD.'s operating cash flow was ₹0 while its capital expenditure stood at ₹0.

Comparatively, CIPLA LTD. paid ₹0.21 in dividends in 2024.

Other key metrics

Current Trading Price
₹1239.25
52-Week High
₹1277.55
52-Week Low
₹845.1433
Analyst Target Price

CIPLA LTD. stock is currently trading at ₹1239.25 per share. It touched a 52-week high of ₹1277.55 and a 52-week low of ₹1277.55. Analysts tracking the stock have a 12-month average target price of .

Its 50-day moving average was ₹1159.12 and 200-day moving average was ₹1026.02 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 3570.2% of the company’s stock are held by insiders while 3635.2% are held by institutions.

Frequently Asked Questions About CIPLA LTD.

The stock symbol (also called stock or share ticker) of CIPLA LTD. is CIPLA

The IPO of CIPLA LTD. took place on

Similar Industry Stocks (Drug Manufacturers-General)

Last Price
Chg
Chg%
₹51.64
-2.85
-5.23%
FGP Limited (500142)
₹6.15
-0.18
-2.84%
Geekay Wires Limited (GEEKAYWIRE)
₹306.75
-6.25
-2%
Patron Exim Ltd (PATRON)
₹9.85
-0.1
-1.01%
₹13.21
-0.16
-1.2%
₹55
-2.57
-4.46%
Alankit Ltd (ALANKIT)
₹11.13
-0.57
-4.87%
₹6.13
0.06
+0.99%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
₹0.14
0.07
+100%
₹0.12
0.04
+45.29%
₹0.96
0.05
+5.4%
₹1.34
-0.35
-20.71%
Humbl Inc (HMBL)
₹0
0
0%

Top Gainers

Last Price
Chg
Chg%
₹0
0
+172200%
₹0
0
+51200%
₹283
280.03
+9428.62%
₹11.2
10.57
+1667.68%
Latch Inc (LTCHW)
₹0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
₹0.19
-123.15
-99.85%
₹0
-0.11
-99.55%
₹0
-0
-97.96%
₹0
-0.01
-93.94%
₹0.01
-0.06
-92.24%

About

Cipla Limited, together with its subsidiaries, manufactures, develops, and sells pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New ventures segments. It also offers active pharmaceutical ingredients; and formulations in various therapeutic areas, such as MI, angina, heart failure, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, HIV, respiratory, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women’s health, ophthalmology, and neuro psychiatry. In addition, the company provides respiratory products, including inhalers and nasal sprays, as well as other respiratory products consists of injectables and biosimilars. Further, it offers Easylax and Easylax L, a liquid paraffin for constipation. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.

Address